Validation of Measures of Satisfaction with and Impact of Continuous and Conventional Glucose Monitoring
Publication: Diabetes Technology & Therapeutics
Volume 12, Issue Number 9
Abstract
Background: The evaluation of patient-reported outcomes (e.g. impact, satisfaction) is important in trials of continuous glucose monitoring (CGM). We evaluated psychometric properties of the CGM Satisfaction Scale (CGM-SAT) and the Glucose Monitoring Survey (GMS).
Methods: CGM-SAT is a 44-item scale on which patients (n = 224) or parents (n = 102) rated their experience with CGM over the prior 6 months. GMS is a 22-item scale on which patients (n = 447) or parents (n = 221) rated the blood glucose monitoring system they were using (home glucose meter with or without CGM) at baseline and 6 months.
Results: The alpha coefficient for the CGM-SAT was ≥0.94 for all respondents and for the GMS was ≥0.84 for all respondents at baseline and 6 months. Parent–youth agreement was 0.52 for the CGM-SAT at 6 months and 0.24 and 0.20 for the GMS at baseline and 6 months for the Standard Care Group, respectively. Test–retest reliability of the GMS at 6 months for controls was r = 0.76 for adult patients, 0.63 for pediatric patients, and 0.43 for parents. Factor analysis isolated measurement factors for the CGM-SAT labeled Benefits of CGM and Hassles of CGM, accounting for 33% and 9% of score variance, respectively. For the GMS, two factors emerged: Glucose Control and Social Complications, accounting for 28% and 9% of variance, respectively. Significant correlations of CGM-SAT with frequency of CGM use between 6 months and baseline and GMS with frequency of conventional daily self-monitoring of blood glucose at baseline support their convergent validity.
Conclusions: The CGM-SAT and GMS are reliable and valid measures of patient-reported CGM outcomes.
Get full access to this article
View all available purchase options and get full access to this article.
References
1.
Klonoff DC. Continuous glucose monitoring: roadmap for 21st century diabetes therapyDiabetes Care2005281231-1239. 1. Klonoff DC: Continuous glucose monitoring: roadmap for 21st century diabetes therapy. Diabetes Care 2005;28:1231–1239.
2.
Diabetes Research in Children Network (DirecNet) Study Group. Accuracy of the modified Continous Glucose Monitoring System (CGMS) sensor in an outpatient setting: results from a Diabetes Research in Children Network (DirecNet) studyDiabetes Technol Ther20057109-114. 2. Diabetes Research in Children Network (DirecNet) Study Group: Accuracy of the modified Continous Glucose Monitoring System (CGMS) sensor in an outpatient setting: results from a Diabetes Research in Children Network (DirecNet) study. Diabetes Technol Ther 2005;7:109–114.
3.
Diabetes Research in Children Network (DirecNet) Study Group. The accuracy of the Guardian RT continuous glucose monitor in children with type 1 diabetesDiabetes Technol Ther200810266-272. 3. Diabetes Research in Children Network (DirecNet) Study Group: The accuracy of the Guardian RT continuous glucose monitor in children with type 1 diabetes. Diabetes Technol Ther 2008;10:266–272.
4.
Diabetes Research in Children Network Study Group. The accuracy of the FreeStyle Navigator™ Continuous Glucose Monitoring System in children with type 1 diabetesDiabetes Care20073059-64. 4. Diabetes Research in Children Network Study Group: The accuracy of the FreeStyle Navigator™ Continuous Glucose Monitoring System in children with type 1 diabetes. Diabetes Care 2007;30:59–64.
5.
Diabetes Research in Children Network Study Group. Continuous glucose monitoring in children with type 1 diabetesJ Pediatr2007151388-393. 5. Diabetes Research in Children Network Study Group: Continuous glucose monitoring in children with type 1 diabetes. J Pediatr 2007;151:388–393.
6.
Diabetes Research in Children Network (DirecNet) Study Group. Prolonged use of continuous glucose monitors in children with type 1 diabetes on continuous subcutaneous insulin infusion or intensive multiple daily injection therapyPediatr Diabetes20091091-96. 6. Diabetes Research in Children Network (DirecNet) Study Group: Prolonged use of continuous glucose monitors in children with type 1 diabetes on continuous subcutaneous insulin infusion or intensive multiple daily injection therapy. Pediatr Diabetes 2009;10:91–96.
7.
Diabetes Research in Children Network Study Group. FreeStyle Navigator Continuous Glucose Monitoring System use in children with type 1 diabetes using glargine-based multiple daily dose regimens: results of a pilot trialDiabetes Care200831525-527. 7. Diabetes Research in Children Network Study Group: FreeStyle Navigator Continuous Glucose Monitoring System use in children with type 1 diabetes using glargine-based multiple daily dose regimens: results of a pilot trial. Diabetes Care 2008;31:525–527.
8.
Deiss DBolinder JRiveline J-PBattelino TBosi ETubiana-Rufi NKerr DPhillip M. Improved glycemic control in poorly controlled patients with type 1 diabetes using real-time continuous glucose monitoringDiabetes Care2006292730-2732. 8. Deiss D, Bolinder J, Riveline J-P, Battelino T, Bosi E, Tubiana-Rufi N, Kerr D, Phillip M: Improved glycemic control in poorly controlled patients with type 1 diabetes using real-time continuous glucose monitoring. Diabetes Care 2006;29:2730–2732.
9.
JDRF CGM Study Group. JDRF randomized clinical trial to assess the efficacy of real-time continuous glucose monitoring in the management of type 1 diabetes: research design and methodsDiabetes Technol Ther200810310-321. 9. JDRF CGM Study Group: JDRF randomized clinical trial to assess the efficacy of real-time continuous glucose monitoring in the management of type 1 diabetes: research design and methods. Diabetes Technol Ther 2008;10:310–321.
10.
The Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group. Continuous glucose monitoring and intensive treatment of type 1 diabetesN Engl J Med20083591464-1476. 10. The Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group: Continuous glucose monitoring and intensive treatment of type 1 diabetes. N Engl J Med 2008;359:1464–1476.
11.
The Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group. The effect of continuous glucose monitoring in well-controlled type 1 diabetesDiabetes Care2009321378-1383. 11. The Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group: The effect of continuous glucose monitoring in well-controlled type 1 diabetes. Diabetes Care 2009;32:1378–1383.
12.
Peyrot MRubin RR. Patient-reported outcomes for an integrated real-time continuous glucose monitoring/insulin pump systemDiabetes Technol Ther20091157-62. 12. Peyrot M, Rubin RR: Patient-reported outcomes for an integrated real-time continuous glucose monitoring/insulin pump system. Diabetes Technol Ther 2009;11:57–62.
13.
Diabetes Research in Children Network (DirecNet) Study Group. Youth and parent satisfaction with clinical use of the Glucowatch G2 Biographer in the management of pediatric type 1 diabetesDiabetes Care2005281929-1935. 13. Diabetes Research in Children Network (DirecNet) Study Group: Youth and parent satisfaction with clinical use of the Glucowatch G2 Biographer in the management of pediatric type 1 diabetes. Diabetes Care 2005;28:1929–1935.
14.
Diabetes Research in Children Network (DirecNet) Study Group. Psychological aspects of continuous glucose monitoring in pediatric type 1 diabetesPediatr Diabetes2006732-38. 14. Diabetes Research in Children Network (DirecNet) Study Group: Psychological aspects of continuous glucose monitoring in pediatric type 1 diabetes. Pediatr Diabetes 2006;7:32–38.
15.
Gibb IParnham AFonfrede MLecock F. Multicenter evaluation of Tosoh glycohemoglobin analyzerClin Chem1999451833-1841. 15. Gibb I, Parnham A, Fonfrede M, Lecock F: Multicenter evaluation of Tosoh glycohemoglobin analyzer. Clin Chem 1999;45:1833–1841.
Information & Authors
Information
Published In
Diabetes Technology & Therapeutics
Volume 12 • Issue Number 9 • September 2010
Pages: 679 - 684
PubMed: 20799388
Copyright
Copyright 2010, Mary Ann Liebert, Inc.
History
Published in print: September 2010
Published online: 14 August 2010
Topics
Authors
Author Disclosure Statement
The following is a listing of relationships of the investigators with companies that make products relevant to the manuscript between July 1, 2006 and present. Research funds where listed below were provided to the legal entity that employs the individual and not directly to the individual: J.M.B. reports having received honoraria from Abbott Diabetes Care, Inc. and Medtronic MiniMed, Inc. C.K. reports having received consulting fees from Medtronic MiniMed, Inc. L.L. reports having received consulting fees from Lifescan, Inc., consulting fees and a speaker honorarium from Abbott Diabetes Care, Inc., and consulting fees and research funding from Medtronic MiniMed, Inc. W.V.T. reports having received consulting fees from Medtronic MiniMed, Inc.
Metrics & Citations
Metrics
Citations
Export Citation
Export citation
Select the format you want to export the citations of this publication.
View Options
Get Access
Access content
To read the fulltext, please use one of the options below to sign in or purchase access.⚠ Society Access
If you are a member of a society that has access to this content please log in via your society website and then return to this publication.